Payment overview · 2025
General Payments
$688.02
36 reported records · 11 companies
Healthcare provider profile · identity verified
David P Guthrie, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DYERSBURG, TN · NPI 1750375291
Verified facts
What the public records show
CMS Open Payments records show David P Guthrie, MD received $688.02 in general payments during 2025 across 36 reported records.
Novo Nordisk Inc accounted for 31.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 348 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $218.40 | 31.7% | 13 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $176.61 | 25.7% | 7 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $74.25 | 10.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.00 | 6.1% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $37.83 | 5.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.41 | 4.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.40 | 4.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.38 | 3.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.50 | 3.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.16 | 2.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.08 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $688.02 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $198.67 | 12 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $176.61 | 7 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $74.25 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $61.85 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.00 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $37.83 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.41 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.40 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.40 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.16 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 301 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 164 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
348 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
164 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
301 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 1552 | 335 |
| Amlodipine Besylate | Amlodipine Besylate | 1477 | 323 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1111 | 225 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1081 | 219 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1009 | 200 |
| Furosemide | Furosemide | 936 | 151 |
| Gabapentin | Gabapentin | 861 | 171 |
| Potassium Chloride | Potassium Chloride | 778 | 115 |
| Duloxetine Hcl | Duloxetine Hcl | 728 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 662 | 175 |
| Alprazolam | Alprazolam | 660 | 104 |
| Sertraline Hcl | Sertraline Hcl | 652 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 649 | 113 |
| Metformin Hcl Er | Metformin Hcl | 578 | 141 |
| Omeprazole | Omeprazole | 563 | 117 |
| Lisinopril | Lisinopril | 530 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 505 | 119 |
| Mirtazapine | Mirtazapine | 486 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 484 | 101 |
| Famotidine | Famotidine | 465 | 72 |
| Pravastatin Sodium | Pravastatin Sodium | 458 | 90 |
| Metoprolol Tartrate | Metoprolol Tartrate | 444 | 92 |
| Donepezil Hcl | Donepezil Hcl | 435 | 45 |
| Spironolactone | Spironolactone | 398 | 87 |
| Ezetimibe | Ezetimibe | 391 | 85 |
| Carvedilol | Carvedilol | 374 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 349 | 66 |
| Jardiance | Empagliflozin | 348 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 343 | 93 |
| Lorazepam | Lorazepam | 334 | 46 |
| Paroxetine Hcl | Paroxetine Hcl | 330 | 20 |
| Eliquis | Apixaban | 301 | 51 |
| Hydralazine Hcl | Hydralazine Hcl | 291 | 59 |
| Trazodone Hcl | Trazodone Hcl | 277 | 48 |
| Divalproex Sodium | Divalproex Sodium | 266 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 256 | 25 |
| Allopurinol | Allopurinol | 248 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 247 | 78 |
| Glimepiride | Glimepiride | 234 | 68 |
| Citalopram Hbr | Citalopram Hydrobromide | 226 | 39 |
| Metformin Hcl | Metformin Hcl | 220 | 28 |
| Buspirone Hcl | Buspirone Hcl | 214 | 41 |
| Ropinirole Hcl | Ropinirole Hcl | 209 | 45 |
| Simvastatin | Simvastatin | 201 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 199 | 35 |
| Xarelto | Rivaroxaban | 184 | 17 |
| Meloxicam | Meloxicam | 172 | 46 |
| Ozempic | Semaglutide | 164 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 160 | 24 |
| Montelukast Sodium | Montelukast Sodium | 154 | 15 |
| Prednisone | Prednisone | 152 | 38 |
| Amitriptyline Hcl | Amitriptyline Hcl | 147 | 17 |
| Baclofen | Baclofen | 136 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 133 | 37 |
| Alendronate Sodium | Alendronate Sodium | 130 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 16 |
| Farxiga | Dapagliflozin Propanediol | 127 | 12 |
| Olanzapine | Olanzapine | 127 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 116 | suppressed |
| Myrbetriq | Mirabegron | 116 | suppressed |
| Ramipril | Ramipril | 113 | 28 |
| Topiramate | Topiramate | 113 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 107 | 32 |
| Glipizide Er | Glipizide | 106 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 106 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 105 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 40 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 103 | 62 |
| Azithromycin | Azithromycin | 101 | 83 |
| Memantine Hcl | Memantine Hcl | 101 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 99 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 98 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 98 | 17 |
| Atenolol | Atenolol | 97 | 16 |
| Cefuroxime | Cefuroxime Axetil | 94 | 69 |
| Tramadol Hcl | Tramadol Hcl | 94 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 93 | suppressed |
| Celecoxib | Celecoxib | 92 | 23 |
| Clonazepam | Clonazepam | 89 | 13 |
| Januvia | Sitagliptin Phosphate | 89 | 12 |
| Promethazine Hcl | Promethazine Hcl | 89 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 60 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 82 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 82 | suppressed |
| Methylprednisolone | Methylprednisolone | 81 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 80 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 78 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 76 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 73 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 71 | 24 |
| Rivastigmine | Rivastigmine | 70 | suppressed |
| Nifedipine Er | Nifedipine | 69 | 16 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 65 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 65 | suppressed |
| Synthroid | Levothyroxine Sodium | 65 | 16 |
| Lovastatin | Lovastatin | 64 | 14 |
| Cephalexin | Cephalexin | 63 | suppressed |
| Primidone | Primidone | 62 | 12 |
| Valsartan | Valsartan | 62 | 16 |
| Entresto | Sacubitril/Valsartan | 61 | suppressed |
| Lamotrigine | Lamotrigine | 60 | suppressed |
| Linzess | Linaclotide | 57 | 13 |
| Pregabalin | Pregabalin | 56 | suppressed |
| Diazepam | Diazepam | 55 | suppressed |
| Levofloxacin | Levofloxacin | 55 | 40 |
| Trimethoprim | Trimethoprim | 54 | suppressed |
| Aripiprazole | Aripiprazole | 53 | suppressed |
| Creon | Lipase/Protease/Amylase | 53 | suppressed |
| Naproxen | Naproxen | 53 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 53 | 16 |
| Cinacalcet Hcl | Cinacalcet Hcl | 52 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 52 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 51 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 51 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 11 |
| Fluconazole | Fluconazole | 44 | 23 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 43 | suppressed |
| Nystatin | Nystatin | 43 | 22 |
| Bupropion Xl | Bupropion Hcl | 42 | 13 |
| Cilostazol | Cilostazol | 42 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 30 |
| Estradiol | Estradiol | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Gemfibrozil | Gemfibrozil | 36 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 36 | suppressed |
| Acyclovir | Acyclovir | 35 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Amantadine | Amantadine Hcl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 26 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 32 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 23 |
| Fosinopril Sodium | Fosinopril Sodium | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 15 |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 27 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 26 | 12 |
| Hydroxyurea | Hydroxyurea | 26 | suppressed |
| Lactulose | Lactulose | 26 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 24 | 17 |
| Famciclovir | Famciclovir | 22 | 14 |
| Methylphenidate Hcl | Methylphenidate Hcl | 22 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 21 | 16 |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Haloperidol | Haloperidol | 21 | suppressed |
| K-Phos Original | Potassium Phosphate,monobasic | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 13 |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | 11 |
| Mometasone Furoate | Mometasone Furoate | 18 | 13 |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Novolin R | Insulin Regular, Human | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Phenobarbital | Phenobarbital | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Insulin Aspart | Insulin Aspart | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $688.02 · 36 records | Novo Nordisk Inc | Arikayce, Cologuard Collection Kit, ELIQUIS, Hillrom - Vest System Model 105 Home Care, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, Wegovy, YUPELRI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error